HRGN · XBRL financial data

Harvard Apparatus Regenerative Technology financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (HRGN's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue	0	0	—	—	—	—
Revenue from contracts with customers	—	—	—	103	430	704
Cost of revenue	—	—	—	24	270	646
Research and development	2,069	1,592	1,742	3,062	2,310	2,653
Selling, general and administrative	3,256	7,044	4,411	—	—	—
General and administrative	—	—	4,411	5,713	5,022	4,253
Total operating expenses	5,325	8,636	6,153	9,093	—	—
Operating income (loss)	(5,325)	(8,636)	(6,153)	(8,990)	(7,726)	(6,915)
Interest income	—	—	—	64	32	37
Interest expense	—	—	9	14	38	8
Other income (expense)	(3)	70	(9)	(5)	0	—
Income tax expense (benefit)	—	—	—	—	0	0
Net income (loss)	(4,865)	(7,978)	(6,073)	(8,945)	(7,732)	(6,869)
Earnings per share, basic USD per share	(0.55)	(0.79)	(0.54)	(0.67)	(0.52)	(0.42)
Earnings per share, diluted USD per share	(0.55)	(0.79)	(0.55)	(0.67)	—	—
Weighted average shares, basic thousands of shares	8,794	10,062	11,350	13,456	14,789	16,517
Weighted average shares, diluted thousands of shares	8,794	10,062	11,350	13,456	—	—

Fiscal years (HRGN's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	1,076	1,292	1,241	432	2,486	1,352
Short-term investments	—	—	—	1,200	—	—
Accounts receivable	—	—	—	4	231	16
Inventory	—	—	—	50	80	16
Prepaid and other current assets	524	295	79	87	347	427
Total current assets	1,677	1,587	1,594	783	3,234	1,829
Property and equipment, net	217	110	49	25	11	6
Right-of-use asset	182	169	147	48	293	195
Total assets	2,076	1,866	2,400	2,614	4,442	2,677
Accounts payable	31	676	682	445	452	454
Total current liabilities	756	4,836	1,363	968	1,021	1,534
Lease liability, non-current	75	59	48	0	199	86
Total liabilities	951	4,895	1,411	968	1,220	1,620
Accumulated deficit	(68,960)	(76,938)	(83,011)	(91,956)	(99,688)	(106,557)
Total stockholders' equity	1,125	(3,029)	(3,191)	1,646	3,222	1,057
Total liabilities and equity	2,076	1,866	2,400	2,614	4,442	2,677
Common shares outstanding (cover page) thousands of shares	9,388	10,761	12,206	13,947	15,919	17,581

Fiscal years (HRGN's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(4,865)	(7,978)	(6,073)	(8,945)	(7,732)	(6,869)
Stock-based compensation	1,144	980	1,031	3,461	2,402	2,010
Net cash from operating activities	(4,041)	(2,628)	(5,106)	(6,939)	(4,852)	(3,828)
Purchases of property and equipment	7	0	5	11	0	—
Net cash from investing activities	(7)	0	(5)	(11)	0	—
Proceeds from issuing common stock	—	—	5,060	5,992	6,482	2,700
Share repurchases	42	0	—	—	—	—
Net cash from financing activities	4,161	2,844	5,060	6,141	6,912	2,700
Net change in cash	113	216	(51)	(809)	2,054	(1,134)

SIC 3841 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 3841 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Harvard Apparatus Regenerative Technology	351	414	(569)*	17.6M	0.6 quarters	Q2 FY26 10-QJun 30, 2026
RetinalGenix Technologies	27	not reported	(137)*	18.8M	0.2 quarters	Q2 FY26 10-QJun 30, 2026
Beyond Air	5,509	1,768	(4,946)	957,631	2.0 quarters	Q1 FY27 10-QJun 30, 2026
NutriBand	3,422	438	(585)*	12.2M	—	Q2 FY27 10-QJul 31, 2026
Nexalin Technology	1,005	12	(1,802)*	22.0M	0.6 quarters	Q2 FY26 10-QJun 30, 2026
Iridex	4,680	12,566	174*	17.6M	—	Q2 FY26 10-QJul 4, 2026
Biotricity	467	4,277	507	19.9M	—	Q1 FY27 10-QJun 30, 2026
VASO	38,291	not reported	17,444*	176.0M	—	Q2 FY26 10-QJun 30, 2026
Envoy Medical	19,679	51	(5,456)*	77.2M	3.6 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.